Table 4.
Simple and multiple regression analysis of factors associated with survival in 82 patients with HCC treated with TACE (patients were divided into two groups: survival 24 months or shorter, and survival longer than 24 months).
| Parameters | Survival ≤24 months | Survival >24 months | P value simple analysis | P value multiple analysis |
|---|---|---|---|---|
| Mean age (years) | 68 | 68 | 0.740 | 0.571 |
| Sex (F) | 12/51 (24) | 4/32 (13) | 0.511 | 0.595 |
| PPLE | 15/51 (29) | 17/32 (53) | 0.012 | 0.017 |
| First PPLE treatment* | 10/51 (20) | 10/32 (31) | 0.056 | - |
| Largest tumor >8 cm | 11/51 (22) | 7/32 (22) | 0.882 | 0.188 |
| Single tumors compared to multiple | 24/51 (47) | 11/32 (34) | 0.938 | 0.286 |
| Unilobar tumors compared to bilobar | 33/51 (65) | 23/32 (72) | 0.263 | 0.172 |
| AFP >400 μg/L | 40/49 (82) | 26/28 (93) | 0.233 | 0.195 |
| Albumin < 35 g/L | 35/50 (70) | 14/31 (45) | 0.250 | 0.783 |
| CRP < 10 mg/L | 33/50 (66) | 22/27 (81) | 0.089 | 0.084 |
Values are given as n (%) unless otherwise indicated.
*First PPLE treatment was not included in the multivariate analysis.
AFP, alpha-fetoprotein; CRP, C-reactive protein; HCC, hepatocellular carcinoma; mRECIST, modified Response Evaluation Criteria in Solid Tumors; OR, objective response; PPLE, peritumoral portal lipiodol enhancement; TACE, transarterial chemoembolization.